biotech

Generate Biomedicines Sets IPO Price at $16 for Asthma Solutions

Generate Biomedicines, an AI-driven biotech firm focused on asthma treatment, has successfully set its IPO price at $16. This funding will enhance its innovative research in immunology and oncology.